Abstract
During the last thirty years, part of the scientific community focused on the mechanisms by which a naturally occurring protein called cellular prion (PrPc) converts into a protease-resistant isoform (PrPsc) responsible for fatal Transmissible Spongiform Encephalopathies (TSE). Concomitantly, the physiology of PrPc has also been studied. PrPc undergoes proteolytic attacks leading to both membrane-attached and secreted fragments, the nature of which differs in normal and TSE-affected human brains. Does proteolysis of PrPc correspond to an inactivating mechanism impairing the biological function of the protein, or alternatively, does it represent a maturation process allowing the produced fragments to trigger their own physiological function? Here we review the mechanisms involved in the production of PrPc catabolites and we focus on the function of PrPc and its derived fragments in the cell death/ survival regulation in the nervous system.
Keywords: ADAM, α-secretase-derived fragments, apoptosis, βAPP, cellular Prion protein, neuroprotection, p53, PRNP gene, infectious agent, Creutzfeld-Jacob Disease, synthetic peptide, proteolysis, neurodegeneration, brain pathologies, amyloid plaques
Current Molecular Medicine
Title: Cellular Prion and its Catabolites in the Brain: Production and Function
Volume: 12 Issue: 3
Author(s): M.-V. Guillot-Sestier and F. Checler
Affiliation:
Keywords: ADAM, α-secretase-derived fragments, apoptosis, βAPP, cellular Prion protein, neuroprotection, p53, PRNP gene, infectious agent, Creutzfeld-Jacob Disease, synthetic peptide, proteolysis, neurodegeneration, brain pathologies, amyloid plaques
Abstract: During the last thirty years, part of the scientific community focused on the mechanisms by which a naturally occurring protein called cellular prion (PrPc) converts into a protease-resistant isoform (PrPsc) responsible for fatal Transmissible Spongiform Encephalopathies (TSE). Concomitantly, the physiology of PrPc has also been studied. PrPc undergoes proteolytic attacks leading to both membrane-attached and secreted fragments, the nature of which differs in normal and TSE-affected human brains. Does proteolysis of PrPc correspond to an inactivating mechanism impairing the biological function of the protein, or alternatively, does it represent a maturation process allowing the produced fragments to trigger their own physiological function? Here we review the mechanisms involved in the production of PrPc catabolites and we focus on the function of PrPc and its derived fragments in the cell death/ survival regulation in the nervous system.
Export Options
About this article
Cite this article as:
Guillot-Sestier M.-V. and Checler F., Cellular Prion and its Catabolites in the Brain: Production and Function, Current Molecular Medicine 2012; 12 (3) . https://dx.doi.org/10.2174/156652412799218912
DOI https://dx.doi.org/10.2174/156652412799218912 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Metabolic Stress and Inflammation: Implication in Treatment for Neurological Disorders
CNS & Neurological Disorders - Drug Targets MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Neural Stem Cell Transplantation and CNS Diseases
CNS & Neurological Disorders - Drug Targets Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials Analgesic and Antineuropathic Drugs Acting Through Central Cholinergic Mechanisms
Recent Patents on CNS Drug Discovery (Discontinued) Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Association Between Seizures and Diabetes Mellitus: A Comprehensive Review of Literature
Current Diabetes Reviews Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry N-Heterocyclic Dipeptide Aldehyde Calpain Inhibitors
Protein & Peptide Letters Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Antioxidant, Antimicrobial Activity and Medicinal Properties of Grewia asiatica L.
Medicinal Chemistry Cysteinet Dysregulation in Muscular Dystrophies: A Pathogenic Network Susceptible to Therapy
Current Medicinal Chemistry Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Gender Related Issues in the Management of Heart Failure
Current Pharmaceutical Design Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Hypoxia-Inducible Factor-1α Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain
Current Neurovascular Research Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition